Literature DB >> 25117704

Polo-like kinase 4 inhibition: a strategy for cancer therapy?

Andrew J Holland1, Don W Cleveland2.   

Abstract

In this issue of Cancer Cell, Mason and colleagues describe the development of a Polo-like kinase 4 (PLK4) inhibitor (CFI-400945), with promising activity against tumors formed in mice from patient-derived tumor tissue. A clinical trial has been initiated, but questions remain as to whether PLK4 is the only relevant therapeutic target.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25117704      PMCID： PMC4148003          DOI： 10.1016/j.ccr.2014.07.017

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  10 in total

Review 1.  Mitotic drivers--inhibitors of the Aurora B Kinase.

Authors:  Nicholas Keen; Stephen Taylor
Journal:  Cancer Metastasis Rev       Date:  2009-06       Impact factor: 9.264

Review 2.  Centrioles, centrosomes, and cilia in health and disease.

Authors:  Erich A Nigg; Jordan W Raff
Journal:  Cell       Date:  2009-11-13       Impact factor: 41.582

Review 3.  Polo-like kinases: structural variations lead to multiple functions.

Authors:  Sihem Zitouni; Catarina Nabais; Swadhin Chandra Jana; Adán Guerrero; Mónica Bettencourt-Dias
Journal:  Nat Rev Mol Cell Biol       Date:  2014-07       Impact factor: 94.444

Review 4.  The mighty mouse: genetically engineered mouse models in cancer drug development.

Authors:  Norman E Sharpless; Ronald A Depinho
Journal:  Nat Rev Drug Discov       Date:  2006-08-18       Impact factor: 84.694

5.  Functional characterization of CFI-400945, a Polo-like kinase 4 inhibitor, as a potential anticancer agent.

Authors:  Jacqueline M Mason; Dan Chi-Chia Lin; Xin Wei; Yi Che; Yi Yao; Reza Kiarash; David W Cescon; Graham C Fletcher; Donald E Awrey; Mark R Bray; Guohua Pan; Tak W Mak
Journal:  Cancer Cell       Date:  2014-07-17       Impact factor: 31.743

6.  Plk4 haploinsufficiency causes mitotic infidelity and carcinogenesis.

Authors:  Michael A Ko; Carla O Rosario; John W Hudson; Sarang Kulkarni; Aaron Pollett; James W Dennis; Carol J Swallow
Journal:  Nat Genet       Date:  2005-07-17       Impact factor: 38.330

7.  Plk4 trans-autophosphorylation regulates centriole number by controlling betaTrCP-mediated degradation.

Authors:  Gernot Guderian; Jens Westendorf; Andreas Uldschmid; Erich A Nigg
Journal:  J Cell Sci       Date:  2010-06-01       Impact factor: 5.285

8.  Centrosome amplification can initiate tumorigenesis in flies.

Authors:  Renata Basto; Kathrin Brunk; Tatiana Vinadogrova; Nina Peel; Anna Franz; Alexey Khodjakov; Jordan W Raff
Journal:  Cell       Date:  2008-06-13       Impact factor: 41.582

9.  Functional viability profiles of breast cancer.

Authors:  Rachel Brough; Jessica R Frankum; David Sims; Alan Mackay; Ana M Mendes-Pereira; Ilirjana Bajrami; Sara Costa-Cabral; Rumana Rafiq; Amar S Ahmad; Maria Antonietta Cerone; Rachael Natrajan; Rachel Sharpe; Kai-Keen Shiu; Daniel Wetterskog; Konstantine J Dedes; Maryou B Lambros; Teeara Rawjee; Spiros Linardopoulos; Jorge S Reis-Filho; Nicholas C Turner; Christopher J Lord; Alan Ashworth
Journal:  Cancer Discov       Date:  2011-08-02       Impact factor: 39.397

10.  Polo-like kinase 4 kinase activity limits centrosome overduplication by autoregulating its own stability.

Authors:  Andrew J Holland; Weijie Lan; Sherry Niessen; Heather Hoover; Don W Cleveland
Journal:  J Cell Biol       Date:  2010-01-25       Impact factor: 10.539
  10 in total
  18 in total

Review 1.  Centrosomes and cancer: revisiting a long-standing relationship.

Authors:  Pierre Gönczy
Journal:  Nat Rev Cancer       Date:  2015-11       Impact factor: 60.716

2.  CFI-400945 is not a selective cellular PLK4 inhibitor.

Authors:  Karen Oegema; Robert L Davis; Pablo Lara-Gonzalez; Arshad Desai; Andrew K Shiau
Journal:  Proc Natl Acad Sci U S A       Date:  2018-10-30       Impact factor: 11.205

3.  Reply to Oegema et al.: CFI-400945 and Polo-like kinase 4 inhibition.

Authors:  Masanori Kawakami; Lisa Maria Mustachio; Lin Zheng; Yulong Chen; Jaime Rodriguez-Canales; Barbara Mino; Jonathan M Kurie; Jason Roszik; Pamela Andrea Villalobos; Kelsie L Thu; Jennifer Silvester; David W Cescon; Ignacio I Wistuba; Tak W Mak; Xi Liu; Ethan Dmitrovsky
Journal:  Proc Natl Acad Sci U S A       Date:  2018-10-30       Impact factor: 11.205

4.  Global cellular response to chemical perturbation of PLK4 activity and abnormal centrosome number.

Authors:  Johnny M Tkach; Reuben Philip; Amit Sharma; Jonathan Strecker; Daniel Durocher; Laurence Pelletier
Journal:  Elife       Date:  2022-06-27       Impact factor: 8.713

Review 5.  Clinically Applicable Inhibitors Impacting Genome Stability.

Authors:  Anu Prakash; Juan F Garcia-Moreno; James A L Brown; Emer Bourke
Journal:  Molecules       Date:  2018-05-13       Impact factor: 4.411

Review 6.  PLK4: a promising target for cancer therapy.

Authors:  Yi Zhao; Xin Wang
Journal:  J Cancer Res Clin Oncol       Date:  2019-09-06       Impact factor: 4.553

7.  A Novel CDK2/9 Inhibitor CYC065 Causes Anaphase Catastrophe and Represses Proliferation, Tumorigenesis, and Metastasis in Aneuploid Cancers.

Authors:  Masanori Kawakami; Lisa Maria Mustachio; Yulong Chen; Zibo Chen; Xiuxia Liu; Cheng-Hsin Wei; Jason Roszik; Adam S Kittai; Alexey V Danilov; Xiaoshan Zhang; Bingliang Fang; Jing Wang; John V Heymach; Liliya Tyutyunyk-Massey; Sarah J Freemantle; Jonathan M Kurie; Xi Liu; Ethan Dmitrovsky
Journal:  Mol Cancer Ther       Date:  2020-12-04       Impact factor: 6.261

8.  Binding of STIL to Plk4 activates kinase activity to promote centriole assembly.

Authors:  Tyler C Moyer; Kevin M Clutario; Bramwell G Lambrus; Vikas Daggubati; Andrew J Holland
Journal:  J Cell Biol       Date:  2015-06-22       Impact factor: 10.539

9.  p53 protects against genome instability following centriole duplication failure.

Authors:  Bramwell G Lambrus; Yumi Uetake; Kevin M Clutario; Vikas Daggubati; Michael Snyder; Greenfield Sluder; Andrew J Holland
Journal:  J Cell Biol       Date:  2015-07-06       Impact factor: 10.539

10.  YLZ-F5, a novel polo-like kinase 4 inhibitor, inhibits human ovarian cancer cell growth by inducing apoptosis and mitotic defects.

Authors:  Yongxia Zhu; Zhihao Liu; Yanling Qu; Jun Zeng; Meiqin Yang; Xiaoyi Li; Zhaodi Wang; Junxiang Su; Xueqin Wang; Luoting Yu; Yue Wang
Journal:  Cancer Chemother Pharmacol       Date:  2020-06-09       Impact factor: 3.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.